- Glucotrack filed unaudited pro forma financials reflecting the merger with Lokahi Therapeutics.
- Combined pro forma figures show expanded net operating losses and no current commercial revenue.
- Transaction introduces significant ongoing cash burn and potential shareholder dilution.
?? Negative AI Sentiment (-2.0 / 10)